Solana Staking Market Value Temporarily Surpasses Ethereum; High Lido Liquid Staking Share Raises Centralization Concerns
According to Jinse and Cointelegraph, the total value of SOL tokens staked on the Solana network temporarily surpassed the market value of staked ETH on Ethereum yesterday. On-chain data shows that there are 505,938 independent wallets staking SOL worth $53.9 billion on the Solana network, with an annualized staking yield of 8.31%; Ethereum's on-chain staking involves 34.7 million ETH, valued at $53.93 billion. The high validation threshold of 32 ETH (approximately $50,000) has led many stakers to shift from node staking to liquid staking protocols, which is a key reason for the reduction in native staking on the Ethereum chain. Currently, about $21.5 billion in funds are involved in liquid staking on Ethereum, with Lido accounting for 88% of the market share, heightening concerns over centralization. Ethereum developers are exploring solutions to promote staking decentralization.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Intel Confirms Advancement of Musk's "Terafab" Chip Plan Amid Stock Price Pressure
Intel CEO Pat Gelsinger stated that the company will continue to participate in Elon Musk's Terafab project. Previously, Musk revealed ongoing discussions with TSMC about potential collaboration, which raised market concerns over Intel's position in the project. As a result, Intel's stock price once dropped by 3.9%.
Gold Price Forecast: XAU/USD retraces gains and nears two-month lows at $4,104
BUZZ-Caribou shares plunge as company explores sale and cancels cancer project
October 7 - ** Caribou Biosciences (CRBU.O) shares fell 35.9% in pre-market trading to $0.72 ** Caribou Biosciences announced late Tuesday that it is exploring strategic options, including a potential sale, merger, or other transactions, to maximize shareholder value ** Caribou said it plans to halt development of its allogeneic CAR-T cell therapy programs, including vispa-cel for non-Hodgkin lymphoma and CB-011 for multiple myeloma ** Caribou also stated it will lay off employees and cut costs, with most layoffs expected to be completed by Q4 2026 ** As of June 30, the company held $113.8 millions in cash, cash equivalents, and marketable securities ** As of the previous trading day's close, the company's share price had dropped about 28% year-to-date (Note: For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them only for reader convenience. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation features.)
Crypto prices
More
